Institutional shares held 67.3 Million
1.19M calls
837K puts
Total value of holdings $7.41B
$131M calls
$92.2M puts
Market Cap $7.57B
68,741,904 Shares Out.
Institutional ownership 97.88%
# of Institutions 508


Latest Institutional Activity in LNTH

Top Purchases

Q3 2024
Swedbank Ab Shares Held: 722K ($79.5M)
Q3 2024
Allspring Global Investments Holdings, LLC Shares Held: 191K ($21.1M)
Q3 2024
International Assets Investment Management, LLC Shares Held: 66.9K ($7.37M)
Q3 2024
Harbor Capital Advisors, Inc. Shares Held: 129K ($14.2M)
Q3 2024
Moody Aldrich Partners LLC Shares Held: 38.4K ($4.22M)

Top Sells

Q3 2024
Reinhart Partners, Inc. Shares Held: 1.24M ($137M)
Q3 2024
Peregrine Capital Management LLC Shares Held: 103K ($11.3M)
Q3 2024
Minich Mac Gregor Wealth Management, LLC Shares Held: 79.4K ($8.74M)
Q3 2024
Oak Ridge Investments LLC Shares Held: 40.2K ($4.43M)
Q3 2024
Stanley Laman Group, Ltd. Shares Held: 65.3K ($7.19M)

About LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.


Insider Transactions at LNTH

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
533K Shares
From 20 Insiders
Grant, award, or other acquisition 489K shares
Exercise of conversion of derivative security 44K shares
Sell / Disposition
422K Shares
From 21 Insiders
Bona fide gift 55.9K shares
Open market or private sale 265K shares
Payment of exercise price or tax liability 101K shares

Track Institutional and Insider Activities on LNTH

Follow Lantheus Holdings, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LNTH shares.

Notify only if

Insider Trading

Get notified when an Lantheus Holdings, Inc. insider buys or sells LNTH shares.

Notify only if

News

Receive news related to Lantheus Holdings, Inc.

Track Activities on LNTH